Abhishek Deshpande1, Vinay Pasupuleti2, Priyaleela Thota2, Chaitanya Pant3, David D K Rolston4, Adrian V Hernandez5, Curtis J Donskey2, Thomas G Fraser6. 1. 1Medicine Institute Center for Value Based Care Research,Cleveland Clinic,Cleveland,Ohio. 2. 3Department of Medicine,Division of Infectious Diseases,Case Western Reserve University,Cleveland,Ohio. 3. 4Department of Gastroenterology,University of Kansas Medical Center,Kansas City,Kansas. 4. 5Department of Internal Medicine,Geisinger Medical Center,Danville,Pennsylvania. 5. 6Postgraduate and Medical Schools,Universidad Peruana de Ciencias Aplicadas (UPC),Lima,Peru. 6. 2Department of Infectious Diseases,Medicine Institute,Cleveland Clinic,Cleveland,Ohio.
Abstract
OBJECTIVE: An estimated 20-30% of patients with primary Clostridium difficile infection (CDI) develop recurrent CDI (rCDI) within 2 weeks of completion of therapy. While the actual mechanism of recurrence remains unknown, a variety of risk factors have been suggested and studied. The aim of this systematic review and meta-analysis was to evaluate current evidence on the risk factors for rCDI. DESIGN: We searched MEDLINE and 5 other databases for subject headings and text related to rCDI. All studies investigating risk factors of rCDI in a multivariate model were eligible. Information on study design, patient population, and assessed risk factors were collected. Data were combined using a random-effects model and pooled relative risk ratios (RRs) were calculated. RESULTS: A total of 33 studies (n=18,530) met the inclusion criteria. The most frequent independent risk factors associated with rCDI were age≥65 years (risk ratio [RR], 1.63; 95% confidence interval [CI], 1.24-2.14; P=.0005), additional antibiotics during follow-up (RR, 1.76; 95% CI, 1.52-2.05; P<.00001), use of proton-pump inhibitors (PPIs) (RR, 1.58; 95% CI, 1.13-2.21; P=.008), and renal insufficiency (RR, 1.59; 95% CI, 1.14-2.23; P=.007). The risk was also greater in patients previously on fluoroquinolones (RR, 1.42; 95% CI, 1.28-1.57; P<.00001). CONCLUSIONS: Multiple risk factors are associated with the development of rCDI. Identification of modifiable risk factors and judicious use of antibiotics and PPI can play an important role in the prevention of rCDI.
OBJECTIVE: An estimated 20-30% of patients with primary Clostridium difficileinfection (CDI) develop recurrent CDI (rCDI) within 2 weeks of completion of therapy. While the actual mechanism of recurrence remains unknown, a variety of risk factors have been suggested and studied. The aim of this systematic review and meta-analysis was to evaluate current evidence on the risk factors for rCDI. DESIGN: We searched MEDLINE and 5 other databases for subject headings and text related to rCDI. All studies investigating risk factors of rCDI in a multivariate model were eligible. Information on study design, patient population, and assessed risk factors were collected. Data were combined using a random-effects model and pooled relative risk ratios (RRs) were calculated. RESULTS: A total of 33 studies (n=18,530) met the inclusion criteria. The most frequent independent risk factors associated with rCDI were age≥65 years (risk ratio [RR], 1.63; 95% confidence interval [CI], 1.24-2.14; P=.0005), additional antibiotics during follow-up (RR, 1.76; 95% CI, 1.52-2.05; P<.00001), use of proton-pump inhibitors (PPIs) (RR, 1.58; 95% CI, 1.13-2.21; P=.008), and renal insufficiency (RR, 1.59; 95% CI, 1.14-2.23; P=.007). The risk was also greater in patients previously on fluoroquinolones (RR, 1.42; 95% CI, 1.28-1.57; P<.00001). CONCLUSIONS: Multiple risk factors are associated with the development of rCDI. Identification of modifiable risk factors and judicious use of antibiotics and PPI can play an important role in the prevention of rCDI.
Authors: Daryl Ramai; Khoi Paul Dang-Ho; Chris Lewis; Paul J Fields; Andrew Ofosu; Mohamed Barakat; Ali Aamar; Emmanuel Ofori; Jonathan Lai; Gandhi Lanke; Amaninder Dhaliwal; Madhavi Reddy; James Gasperino Journal: Int J Colorectal Dis Date: 2020-06-17 Impact factor: 2.571
Authors: Ola H Negm; Mohamed R Hamed; Elizabeth M Dilnot; Clifford C Shone; Izabela Marszalowska; Mark Lynch; Christine E Loscher; Laura J Edwards; Patrick J Tighe; Mark H Wilcox; Tanya M Monaghan Journal: Clin Vaccine Immunol Date: 2015-07-15
Authors: Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei Journal: Pharmacotherapy Date: 2018-02-22 Impact factor: 4.705
Authors: Seth R Shaffer; Zoann Nugent; Andrew Walkty; B Nancy Yu; Lisa M Lix; Laura E Targownik; Charles N Bernstein; Harminder Singh Journal: CMAJ Open Date: 2020-11-16